Natera (NTRA) just reported record Q1 2026 results, with revenue of US$696.64 million and more than one million tests processed. A wider net loss and raised full year guidance have sharpened investor focus on profitability.

The share price reaction to the mixed Q1 update has been sharp, with a 1 day share price return of down 11.6% and a year to date share price return of down 15.1%. This comes even though the 1 year total shareholder return of 23.5% and 3 year total shareholder return of about 2.7x still point to strong longer term momentum.

If earnings volatility in a fast growing healthcare testing business catches your attention, it may be worth widening your search and checking out 35 healthcare AI stocks

With Natera now valued at about US$27.8b and the stock sitting roughly 34% below the average analyst price target, the key question is whether recent weakness reflects an undervalued growth story or a market that is already pricing in future gains.

Most Popular Narrative: 25% Undervalued

Natera's most followed valuation narrative points to a fair value of about $259 per share, compared with the last close of $194.24. This puts the spotlight on what is built into those assumptions.

Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.

Want to see what sits behind that confidence in future expansion? Revenue growth expectations, margin shifts, and a rich R&D pipeline all feed into this fair value story. The narrative connects product traction, reimbursement assumptions, and earnings power in a way the current share price does not fully reflect.

Result: Fair Value of $259 (UNDERVALUED)

However, that upside story still hinges on successful clinical trial outcomes and reimbursement decisions, while rising R&D and SG&A spending could keep profitability under pressure longer than bulls expect.

Next Steps

With both risks and rewards in play, do you feel the story so far leans too positive or too cautious? Act quickly, review the data, and weigh both sides yourself with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop here, you could miss stocks that better fit your risk, income, or growth goals. Use structured tools to filter the market efficiently.

• Target potential mispricings by scanning for companies that combine quality metrics with attractive valuations through the 50 high quality undervalued stocks.
• Strengthen your income stream by focusing on businesses with higher yields that still prioritise resilience using the 12 dividend fortresses.
• Prioritise capital preservation by filtering for companies with steadier financial profiles and lower risk scores via the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.